NVO: collect full premium from these short puts when they expired worthless on 15th Aug.
NVO is up 2.6% to close at $52.41 and on its 2nd positive week after dropping almost 33% in end July.
I believe NVO is oversold given its strong diabetic and weigh loss drugs sector but also wary of its eroding position in US due to legal knockoffs and also strong competitions from LLY.
Margin would eventually come down, so will see how NVO trades in the coming quarters after management changes.
| Side | Price | Filled | Realized P&L |
|---|---|---|
| Buy Close | 0.00 1Lot(s) | +100.00% Closed |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
- frosti·2025-08-18Great insights on NVO! Keep it up! [Applaud][Heart]LikeReport
- KSR·2025-08-18👍LikeReport
